Research Centre of Personalized Oncology

Research Centre of Personalized Oncology

Head of the Centre — Konstantin Samochernykh.

Major tasks

The scientific significance of fundamental developments in the field of oncology as part of the work of the WCRC for Personalized Medicine is determined by the use of the latest gene expression analysis technologies, including single cell sequencing, genomic analysis combined with epigenetic profiling and high-throughput sequencing.

Data on the genomic structure of solid and hematopoietic tumors obtained using the material of existing and future bioresource collections, combined with the possibility of detailed patient phenotyping at medical centers of the Consortium will allow developing new criteria that determine the chemo- and radiosensitivity of tumors, creating genetic diagnostic systems and new genetically engineered drugs for cancer treatment, determining new genetic markers for personalized targeted therapy for a number of tumors.

Important areas of the Oncology program are the study of the fundamental mechanisms of drugs utilizing chimeric antigen receptors, the use of genetically modified immune cells and the search for methods to create biomedical cell products of this kind.

Focus areas

  • Molecular and genetic profiling of CNS tumors for personalized combined therapy.
  • Searching for new molecular and genetic markers for the prediction of the clinical course of neuroendocrine tumors.
  • Molecular profiling of pancreatic and pancreato-biliary tumors and borderline neoplasms to determine personalized surgical and chemotherapy tactics.
  • Chimeric antigen receptor T cells (CAR-T) for colorectal cancer therapy using a new method of bispecific receptors.
  • Chimeric antigen receptor T cells (CAR-T) for the treatment of multiple myeloma using a new type of costimulatory domains.
  • Immunological markers as predictors of response to tyrosine kinase inhibitors and targets for therapy for myeloproliferative disorders.
  • Single cell sequencing as a method for determining tumor heterogeneity and therapy strategy.
  • Studying the immune landscape of acute leukemia to create a patient's individual immune profile in order to personalize therapy based on this profile.
  • Developing methods to increase the efficacy and safety of haploidentical bone marrow transplantation based on the studied characteristics of immune recovery and cell-mediated adaptive immune technologies.
  • Developing of RAS70 peptide agent against membrane-bound HSP70 on cancer cells for targeted intraoperative imaging of malignant tumors.
  • Developing and obtaining oncolytic bacterial and viral strains for the treatment of intestinal, pancreato-biliary and brain tumors.
  • Creating a line of radiopharmaceuticals for determining the radiation phenotype of malignant tumors of various sites in order to personalize antitumor treatment.
  • Developing an approach to improve the long-term outcomes of treatment for cancer patients by using personalized microbial therapy.
  • Studying the role of microbiota in the development and progression of female genital tumors.
  • Developing a neural network algorithm for early diagnosis of tumors of the female reproductive system (cervical cancer) based on colposcopic screening.
  • Creating programmes for the analysis of endoscopic ultrasound videos and images based on artificial intelligence for higher diagnostic accuracy.
  • Developing personalized minimally invasive and palliative endoscopic techniques for the treatment of pancreatobiliary tumors and endoscopic administration of chemotherapy drugs.
  • Personalizing the management of cancer patients in order to preserve fertility.
  • Developing a personalized decision support system for choosing the tactics in patients with malignant tumors of various sites and severe cardiovascular comorbidities.


Major publications


Konstantin Samochernykh, Head of the Centre